Hemp Compounds Show Promise for Managing Blood Sugar Through Gut-Based Mechanisms
- Researchers identified three hemp seed compounds—Cannabisin A, Cannabisin B, and Cannabisin F—that may help regulate blood sugar by affecting glucose processing in the gut.
- Cannabisin A and Cannabisin F effectively inhibit the enzyme α-glucosidase, slowing carbohydrate breakdown and reducing post-meal blood sugar spikes, with effects comparable or superior to the diabetes drug acarbose.
- Cannabisin B enhances the release of the hormone GLP-1, aiding insulin regulation and blood sugar control through a complementary metabolic pathway rather than directly blocking sugar absorption.
- All three compounds are predicted to act locally in the gut, potentially minimizing systemic side effects, with Cannabisin B showing a lower likelihood of causing gastrointestinal issues; however, further human studies are needed to confirm safety and efficacy.
Researchers from Konyang University and the Korea Institute of Oriental Medicine report that several compounds derived from hemp seeds may help regulate blood sugar by targeting how glucose is processed in the gut, according to a study published in Biomedicine & Pharmacotherapy.
The study focused on three naturally occurring compounds—Cannabisin A, Cannabisin B, and Cannabisin F—found in hemp seed hulls. Researchers found that two of these compounds, Cannabisin A and Cannabisin F, were particularly effective at slowing the breakdown of carbohydrates in the intestine by inhibiting the enzyme α-glucosidase. This process is similar to how existing diabetes medications like acarbose work, helping to reduce spikes in blood sugar after meals.
In laboratory and animal testing, both compounds significantly reduced post-meal glucose levels, with effects comparable to or stronger than acarbose. They also appeared to influence key glucose transporters in the gut, further limiting how much sugar enters the bloodstream.
Cannabisin B showed a different profile. While it was less effective at directly lowering glucose levels, it enhanced the release of GLP-1, a hormone that helps regulate insulin and blood sugar. This suggests it may work through a complementary pathway, supporting metabolic control rather than directly blocking sugar absorption.
Importantly, all three compounds were predicted to remain largely in the gut rather than entering the bloodstream, which could reduce the risk of systemic side effects. The study also found that Cannabisin B may cause fewer gastrointestinal issues compared to traditional treatments, based on markers tied to gut fermentation.
Researchers say these findings highlight the potential of hemp-derived compounds as next-generation options for managing post-meal blood sugar, though further studies—particularly in humans—will be needed to confirm their effectiveness and safety.